ISU Abxis 
Welcome,         Profile    Billing    Logout  
 6 Products   3 Diseases  6 Products   5 Trials   411 News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fabagal (fabrazyme biosimilar) / ISU Abxis
NCT06081062: Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease

Recruiting
3
24
RoW
Fabagal® (Agalsidase beta), Active comparator (Agalsidase beta)
ISU Abxis Co., Ltd.
Fabry Disease
06/25
12/25
Clotinab (abciximab) / ISU Abxis
2010-019688-12: Prospective placebo controlled trial: Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris during percutaneous coronary interventions under an adjunctive antithrombotic therapy with abciximab.

Ongoing
4
60
Europe
ReoPro, ReoPro, ReoPro
Friedrich-Schiller University Jena, Clinic for Internal Medicine I
Up to 60 patients with stable angina pectoris and planned PCI at the University Clinic of Jena are randomly assigned to the glycoprotein IIb/IIIa receptor antagonist abciximab or placebo. Randomisation takes place after the diagnostic procedure with knowledge of the coronary anatomy. Patients are planned to undergo balloon dilatation with or without implantation of a bare metal stent for a single vessel stenosis. All will undergo periprocedural Doppler analysis.
 
 
2010-022725-16: INTRACORONARY ADMINISTRATION OF TENECTEPLASE VERSUS ABCIXIMAB AS ADJUNCTIVE TREATMENT DURING PRIMARY ANGIOPLASTY IN ACUTE MYOCARDIAL INFARCTION OF ANTERIOR LOCATION ADMINISTRACION INTRACORONARIA DE TENECTEPLASA FRENTE A ABCIXIMAB COMO TRATAMIENTO ADJUNTO DURANTE ANGIOPLASTIA PRIMARIA EN INFARTO AGUDO DE MIOCARDIO DE LOCALIZACION ANTERIOR

Ongoing
3/4
60
Europe
METALYSE, REOPRO, METALYSE, REOPRO
FRANCISCO JOSE MORALES PONCE, GRANT FROM: SUBVENCIONES PARA INVESTIGACION INDEPENDIENTE-DIRECCION GENERAL DE FARMACIA-ESPAÑA
ACUTE MYOCARDIAL INFARCTION INFARTO AGUDO DE MIOCARDIO
 
 
PICASSO, NCT05611242: Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial

Recruiting
3
404
US
MT+CAS with IV-AP, Thrombectomy, MT+CAS with PO-AP, MT+CAT with PO-AP
Mercy Health Ohio
Acute Ischemic Stroke
03/26
05/27
2020-005098-29: OPTI-STEMI is a randomized, non-profit, open label, multicentre phase II trial for the evaluation of new therapeutic strategies to reduce microvascular obstruction and to optimize revascularization in non-culprit stenosis in STEMI myocardial infarction. OPTI-STEMI è uno studio randomizzato, no-profit, open label, multicentrico di fase II per la valutazione di nuove strategie terapeutiche per ridurre l’ostruzione microvascolare e per ottimizzare la rivascolarizzazione in stenosi non-culprit nell’infarto miocardico STEMI.

Ongoing
2
520
Europe
Metoprololo, Atorvastatina, Eparina sodica, Adenosina, Colchicina, Clopidogrel, Ticagrelor, Liraglutide, Prasugrel, Ramipril, Acido acetilsalicilico, Abciximab, [NA], Infusion, Tablet, Solution for injection
DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II, Ministero dell’Istruzione, dell’Università e della Ricerca Progetto MIUR codice 2017PZY5K7
Patients with acute ST-elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MVD) defined by at least one non-culprit stenosis (NCS) with angiographic severity between 30 and 90% Pazienti infarto miocardico acuto con sopraslivellamento del tratto ST (STEMI) e con malattia coronarica multivasale (MVD) definita da almeno una stenosi non culprit (NCS) con severità angiografica tra il 30 ed il 90%, Patients with microvascular obstruction with non-culprit stenosis, i.e. with partial stenosis, between 30% and 90%, of coronary vessels. Pazienti con ostruzione microvascolare con stenosi non-culprit, ossia con stenosi parziale, tra il 30% e il 90%, dei vasi coronarici., Diseases [C] - Cardiovascular Diseases [C14]
 
 
barecetamab (ISU104) / ISU Abxis
NCT03552406: Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors

Active, not recruiting
1
33
RoW
ISU104, A human monoclonal antibody targeting ErbB3, Cetuximab, Erbitux, Epidermal Growth Factor Receptor (EGFR) inhibitor
ISU Abxis Co., Ltd.
Solid Tumor
10/20
12/21
ISU305 (eculizumab biosimilar) / ISU Abxis
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fabagal (fabrazyme biosimilar) / ISU Abxis
NCT06081062: Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease

Recruiting
3
24
RoW
Fabagal® (Agalsidase beta), Active comparator (Agalsidase beta)
ISU Abxis Co., Ltd.
Fabry Disease
06/25
12/25
Clotinab (abciximab) / ISU Abxis
2010-019688-12: Prospective placebo controlled trial: Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris during percutaneous coronary interventions under an adjunctive antithrombotic therapy with abciximab.

Ongoing
4
60
Europe
ReoPro, ReoPro, ReoPro
Friedrich-Schiller University Jena, Clinic for Internal Medicine I
Up to 60 patients with stable angina pectoris and planned PCI at the University Clinic of Jena are randomly assigned to the glycoprotein IIb/IIIa receptor antagonist abciximab or placebo. Randomisation takes place after the diagnostic procedure with knowledge of the coronary anatomy. Patients are planned to undergo balloon dilatation with or without implantation of a bare metal stent for a single vessel stenosis. All will undergo periprocedural Doppler analysis.
 
 
2010-022725-16: INTRACORONARY ADMINISTRATION OF TENECTEPLASE VERSUS ABCIXIMAB AS ADJUNCTIVE TREATMENT DURING PRIMARY ANGIOPLASTY IN ACUTE MYOCARDIAL INFARCTION OF ANTERIOR LOCATION ADMINISTRACION INTRACORONARIA DE TENECTEPLASA FRENTE A ABCIXIMAB COMO TRATAMIENTO ADJUNTO DURANTE ANGIOPLASTIA PRIMARIA EN INFARTO AGUDO DE MIOCARDIO DE LOCALIZACION ANTERIOR

Ongoing
3/4
60
Europe
METALYSE, REOPRO, METALYSE, REOPRO
FRANCISCO JOSE MORALES PONCE, GRANT FROM: SUBVENCIONES PARA INVESTIGACION INDEPENDIENTE-DIRECCION GENERAL DE FARMACIA-ESPAÑA
ACUTE MYOCARDIAL INFARCTION INFARTO AGUDO DE MIOCARDIO
 
 
PICASSO, NCT05611242: Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial

Recruiting
3
404
US
MT+CAS with IV-AP, Thrombectomy, MT+CAS with PO-AP, MT+CAT with PO-AP
Mercy Health Ohio
Acute Ischemic Stroke
03/26
05/27
2020-005098-29: OPTI-STEMI is a randomized, non-profit, open label, multicentre phase II trial for the evaluation of new therapeutic strategies to reduce microvascular obstruction and to optimize revascularization in non-culprit stenosis in STEMI myocardial infarction. OPTI-STEMI è uno studio randomizzato, no-profit, open label, multicentrico di fase II per la valutazione di nuove strategie terapeutiche per ridurre l’ostruzione microvascolare e per ottimizzare la rivascolarizzazione in stenosi non-culprit nell’infarto miocardico STEMI.

Ongoing
2
520
Europe
Metoprololo, Atorvastatina, Eparina sodica, Adenosina, Colchicina, Clopidogrel, Ticagrelor, Liraglutide, Prasugrel, Ramipril, Acido acetilsalicilico, Abciximab, [NA], Infusion, Tablet, Solution for injection
DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II, Ministero dell’Istruzione, dell’Università e della Ricerca Progetto MIUR codice 2017PZY5K7
Patients with acute ST-elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MVD) defined by at least one non-culprit stenosis (NCS) with angiographic severity between 30 and 90% Pazienti infarto miocardico acuto con sopraslivellamento del tratto ST (STEMI) e con malattia coronarica multivasale (MVD) definita da almeno una stenosi non culprit (NCS) con severità angiografica tra il 30 ed il 90%, Patients with microvascular obstruction with non-culprit stenosis, i.e. with partial stenosis, between 30% and 90%, of coronary vessels. Pazienti con ostruzione microvascolare con stenosi non-culprit, ossia con stenosi parziale, tra il 30% e il 90%, dei vasi coronarici., Diseases [C] - Cardiovascular Diseases [C14]
 
 
barecetamab (ISU104) / ISU Abxis
NCT03552406: Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors

Active, not recruiting
1
33
RoW
ISU104, A human monoclonal antibody targeting ErbB3, Cetuximab, Erbitux, Epidermal Growth Factor Receptor (EGFR) inhibitor
ISU Abxis Co., Ltd.
Solid Tumor
10/20
12/21
ISU305 (eculizumab biosimilar) / ISU Abxis
No trials found

Download Options